Last edition
News about "Catalent"
Novo Holdings Completes Acquisition of Catalent
With the completion of the transaction, holders of Catalent common stock are entitled to receive USD 63.50 per share in cash, representing a premium of approximately 47.5 percent to the 60-day volume-weighted average price as of February 2, 2024.
Catalent | 20/12/2024 | By Aishwarya
Siren Biotechnology and Catalent to Manufacture AAV Gene Therapies for Cancer
Siren Biotechnology has signed a strategic partnership with Catalent to support the development and manufacturing of Siren Biotechnology’s AAV immuno-gene therapies.
Catalent | 18/05/2024 | By Aishwarya | 194
The expansion will create approximately 50 new scientific jobs at the site by February 2023
Catalent | 21/10/2022 | By Sudeep Soparkar | 358
Catalent to invest $2.2 M in clinical supply facility
The investment will provide an additional 31,000 square feet, representing a 20 per cent increase in floor space
Catalent | 08/09/2022 | By Sudeep Soparkar | 380
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy